Rezdiffra (Resmetirom) Pharmacokinetics (ADME)

What Is Resmetirom and Why Does Its Liver Selectivity Matter?

Resmetirom is the first and currently only FDA-approved pharmacotherapy specifically for MASH with liver fibrosis. Its clinical utility depends almost entirely on one design feature: preferential accumulation in hepatocytes rather than in cardiac or skeletal muscle tissue. That selectivity is not accidental. It flows directly from the drug's physicochemical properties and the transporter biology of the hepatic sinusoid.

Thyroid hormones exert metabolic effects through two receptor subtypes, THR-alpha and THR-beta. THR-alpha mediates heart rate and bone turnover. THR-beta drives hepatic lipid oxidation, LDL receptor upregulation, and mitochondrial biogenesis. Early pan-thyromimetic compounds failed because they activated both subtypes. Resmetirom binds THR-beta with roughly 28-fold selectivity over THR-alpha, as described in the FDA pharmacology review, which dramatically reduces cardiac adverse signals.

Hepatic Uptake Transporters

After oral absorption, resmetirom enters portal circulation and is taken up by organic anion transporting polypeptides (OATPs), particularly OATP1B1 and OATP1B3, expressed on the basolateral membrane of hepatocytes. OATP1B-mediated hepatic uptake is well-characterized for multiple drugs and explains why hepatic tissue concentrations of resmetirom substantially exceed plasma concentrations. The liver-to-plasma ratio in preclinical models exceeded 50-fold, a finding consistent with the drug's observed systemic tolerability profile.

Clinical Relevance of Selectivity

Because systemic plasma exposure remains relatively low, thyroid-stimulating hormone (TSH) suppression is minimal at therapeutic doses. In MAESTRO-NASH, TSH values were not meaningfully different between the 100 mg resmetirom arm and placebo at 52 weeks, as reported in the primary NEJM publication. This stands in contrast to synthetic T3 analogues that suppress TSH by 30 to 50% at lipid-lowering doses.

Absorption: Oral Bioavailability and Food Effects

Resmetirom is formulated as an immediate-release tablet taken once daily. Absolute oral bioavailability has not been formally published in a standalone study, but the FDA label and pharmacology review indicate moderate systemic exposure that supports once-daily dosing without accumulation to toxic levels.

Tmax and Cmax

Following a single oral dose, peak plasma concentration (Cmax) is reached at approximately 1.5 to 4 hours. A standard high-fat meal delays Tmax by roughly 1 hour and increases Cmax by approximately 30 to 40%, per the Rezdiffra prescribing information. The label recommends administration with food to improve consistency of absorption, though the clinical impact of the fed-state increase in Cmax is considered modest given the drug's wide therapeutic index in hepatic tissue.

Dose Proportionality

Across the 20 mg to 200 mg dose range studied in Phase 1, exposure (AUC and Cmax) increases in an approximately dose-proportional manner. Steady-state plasma concentrations are reached within 7 days of once-daily dosing, with an accumulation ratio of roughly 2-fold compared to a single dose, consistent with a 5-hour half-life and once-daily interval.

Distribution: Protein Binding and Volume

Resmetirom is greater than 99% bound to plasma proteins, predominantly albumin and, to a lesser extent, alpha-1-acid glycoprotein. High plasma protein binding is a shared characteristic of thyroid hormone analogues and contributes to the relatively low volume of distribution at the systemic level. The apparent volume of distribution at steady state is approximately 166 liters, indicating tissue distribution beyond the plasma compartment.

Hepatic Concentrations vs. Plasma

The disconnect between plasma protein binding and hepatic tissue accumulation is mechanistically important. Despite tight plasma binding, OATP1B-mediated active transport into hepatocytes drives intracellular concentrations far above what free plasma drug levels would predict by passive diffusion alone. This active hepatic uptake is saturable, which may partly explain why dose escalation beyond 100 mg does not produce proportional increases in pharmacodynamic effect on liver enzymes.

Metabolism: CYP2C8 and Phase II Pathways

Resmetirom undergoes extensive hepatic metabolism. CYP2C8 is the primary oxidative enzyme responsible, accounting for the majority of Phase I biotransformation. CYP3A4 contributes a minor secondary pathway. CYP2C8 pharmacogenomics and drug interaction data are well-documented in the FDA drug interaction guidance.

Primary Metabolites

The main circulating metabolite identified in human mass balance studies is a glucuronide conjugate formed after Phase I oxidation. This conjugate is pharmacologically inactive and does not contribute to THR-beta agonism. A secondary sulfated metabolite has been identified in bile but represents a minor fraction of total drug-related material in plasma.

Phase II Conjugation

Following CYP2C8-mediated hydroxylation, UDP-glucuronosyltransferases (UGTs), particularly UGT1A1 and UGT1A3, conjugate the oxidized intermediate to glucuronic acid. UGT1A1 polymorphisms affect the glucuronidation of multiple drugs including thyroid hormone analogues, though the clinical significance of UGT1A1 genotype on resmetirom exposure has not been fully characterized in published literature at this time.

Implications for CYP2C8 Drug Interactions

Strong CYP2C8 inhibitors such as gemfibrozil may increase resmetirom plasma exposure by up to 2-fold. The prescribing information lists this as a significant drug interaction requiring dose reduction or avoidance. Gemfibrozil is a prototypical strong CYP2C8 inhibitor used in FDA drug interaction guidance. Conversely, strong CYP2C8 inducers such as rifampin could reduce exposure substantially, though co-administration is unlikely in the MASH population.

Excretion: Fecal and Renal Routes

Resmetirom and its metabolites are eliminated primarily through biliary excretion into feces. In a human radiolabeled mass balance study conducted as part of the NDA package, approximately 82% of administered radioactivity was recovered in feces and roughly 9% in urine, consistent with data summarized in the FDA clinical pharmacology review.

Renal Impairment

Because renal elimination of unchanged drug is minimal, mild-to-moderate renal impairment (eGFR 30 to 89 mL/min/1.73m2) does not meaningfully alter exposure. No dose adjustment is recommended for these patients. Data in severe renal impairment (eGFR <30 mL/min/1.73m2) or end-stage renal disease are limited, and the prescribing information advises caution in those settings.

Hepatic Impairment

This is a clinically nuanced situation. Resmetirom is approved for patients with MASH and fibrosis, many of whom have underlying hepatic dysfunction. In Child-Pugh A (mild) hepatic impairment, pharmacokinetic changes are not clinically significant. In Child-Pugh B (moderate) impairment, AUC increases by approximately 40%, and the label recommends monitoring. The drug has not been studied in Child-Pugh C (severe) impairment, and use is not recommended in that setting. Hepatic impairment classification using Child-Pugh criteria is described in FDA guidance for industry.

Mechanism of Action: How Resmetirom Works at the Molecular Level

Understanding pharmacokinetics is inseparable from understanding the drug's mechanism. Resmetirom enters hepatocytes via OATP transporters, diffuses into the nucleus, and binds the ligand-binding domain of THR-beta as an agonist. This binding triggers conformational changes that release co-repressor complexes and recruit co-activators such as SRC-1 and PGC-1-alpha.

Downstream Metabolic Effects

Activated THR-beta signaling in the liver produces several coordinated effects:

• Upregulation of mitochondrial fatty acid beta-oxidation genes (CPT1A, ACSL1)
• Increased expression of LDL receptors, lowering circulating LDL-C by 13 to 20% at 100 mg
• Suppression of de novo lipogenesis via downregulation of SREBP-1c target genes
• Upregulation of autophagy pathways that clear lipid droplets and misfolded proteins

Thyroid hormone receptor beta signaling in hepatic lipid metabolism is reviewed in detail in this NIH-indexed publication.

Connection to Fibrosis Regression

The fibrosis regression observed in MAESTRO-NASH likely reflects multiple converging mechanisms rather than a single pathway. Reduced hepatic lipotoxicity lowers stellate cell activation signals. Improved mitochondrial function reduces reactive oxygen species that drive TGF-beta secretion. At 52 weeks in MAESTRO-NASH, 24.2% of patients on 100 mg achieved at least one stage of fibrosis improvement without MASH worsening, compared with 14.2% on placebo (P<0.001), as reported in the NEJM primary analysis.

Pharmacodynamic Biomarkers That Confirm On-Target Activity

Plasma pharmacodynamic biomarkers provide a window into hepatic THR-beta engagement that plasma drug concentrations alone cannot offer.

SHBG as a Surrogate for Hepatic THR-beta Activation

Sex hormone-binding globulin (SHBG) is produced exclusively in the liver and its transcription is driven by THR-beta. Resmetirom increases SHBG by 20 to 40% from baseline at steady state, a biomarker relationship described in the resmetirom Phase 2 data published in Gastroenterology. This increase confirms hepatic target engagement and correlates directionally with histological response.

Fibroblast Growth Factor 21 (FGF21)

FGF21 is a hepatokine whose expression is partially under THR-beta regulation. Resmetirom treatment increases FGF21 by approximately 50 to 80% from baseline, as shown in preclinical mechanistic work indexed on PubMed. Elevated FGF21 may contribute to improved adipose tissue insulin sensitivity observed in treated patients.

LDL-C and Triglycerides

In MAESTRO-NASH, 100 mg resmetirom reduced LDL-C by a mean of 16.3% and triglycerides by 22.6% at 52 weeks vs. Placebo, per the NEJM publication. These lipid changes serve as accessible, real-time pharmacodynamic signals that clinicians can monitor between liver biopsies.

Drug Interactions: What Clinicians Need to Know

The MASH patient population commonly takes statins, fibrates, and antidiabetic agents. The drug interaction profile of resmetirom therefore requires careful consideration at the time of prescribing.

CYP2C8 Inhibitors

Gemfibrozil, a strong CYP2C8 inhibitor, is contraindicated or requires dose reduction when co-administered with resmetirom. Moderate CYP2C8 inhibitors such as clopidogrel may increase resmetirom AUC by roughly 50 to 70%. The prescribing information recommends starting at the lower 80 mg dose when moderate CYP2C8 inhibitors cannot be avoided. Clopidogrel as a CYP2C8 inhibitor via its acyl-beta-D-glucuronide metabolite is documented in this PubMed-indexed interaction study.

Statins and OATP Substrates

Resmetirom is an inhibitor of OATP1B1 and OATP1B3 at clinically relevant concentrations. Co-administration with OATP1B substrates such as rosuvastatin, pravastatin, or pitavastatin may increase statin plasma exposure. OATP1B1/1B3 inhibition by small molecules and its clinical consequences are reviewed in this FDA drug interaction guidance-cited publication. The label recommends using the lowest effective statin dose and monitoring for statin-associated myopathy.

P-glycoprotein and BCRP

Resmetirom is also an inhibitor of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Digoxin, a sensitive P-gp substrate, may have increased exposure when co-administered. Monitoring digoxin levels is appropriate in patients requiring both drugs.

Special Populations: Dosing Considerations

Sex and Body Weight

Population pharmacokinetic analyses show no clinically meaningful effect of sex on resmetirom exposure. Body weight above 100 kg is associated with modestly lower AUC, though the exposure difference does not reach a threshold that requires dose adjustment based on current label guidance. Population PK modeling approaches for hepatic drugs are described in FDA guidance.

Age

Patients over 65 years were enrolled in MAESTRO-NASH and represented approximately 15% of the trial population. No age-related pharmacokinetic differences of clinical significance were identified. Renal function decline with age remains the more relevant variable to monitor.

Race and Ethnicity

Limited data exist for non-White subgroups in the resmetirom PK studies. The MAESTRO-NASH trial enrolled predominantly White patients (approximately 78%), as noted in the NEJM baseline characteristics table. Extrapolation of PK parameters to diverse populations requires caution until additional data are published.

MAESTRO-NASH: Connecting Pharmacokinetics to Clinical Outcomes

MAESTRO-NASH was a Phase 3, randomized, double-blind, placebo-controlled trial in 966 patients with biopsy-confirmed MASH and fibrosis stage F1B through F4. Patients received resmetirom 80 mg, 100 mg, or placebo once daily for 52 weeks. The co-primary endpoints were MASH resolution without worsening of fibrosis, and fibrosis improvement of at least one stage without worsening of MASH.

At 100 mg, 25.9% of patients achieved MASH resolution vs. 9.7% on placebo (P<0.001). Fibrosis improvement of at least one stage occurred in 24.2% vs. 14.2% on placebo (P<0.001). These primary efficacy results were published in the New England Journal of Medicine in 2024.

The 80 mg dose produced intermediate results: 19.2% MASH resolution vs. 9.7% placebo (P<0.001), consistent with dose-exposure-response relationships expected from the Phase 2 data. The exposure-response relationship supports the approved dose range and the clinical decision to use 80 mg in patients with moderate fibrosis and 100 mg in those with stage F3 disease.

The Endocrine Society's 2023 clinical practice guideline on nonalcoholic fatty liver disease states: "Pharmacological therapy targeting hepatic lipid metabolism represents a high-priority research and clinical need for patients with MASH who have bridging fibrosis," as published in the Journal of Clinical Endocrinology and Metabolism. Resmetirom is the first agent to satisfy that need with regulatory approval.

Safety Profile Through a Pharmacokinetic Lens

The most common adverse effects of resmetirom are gastrointestinal: nausea (26% at 100 mg vs. 11% placebo) and diarrhea (28% vs. 16%), per the prescribing information and MAESTRO-NASH safety data. These effects are consistent with the enterohepatic circulation of the drug and its metabolites stimulating bile acid flux.

Transient increases in liver enzymes (ALT, AST) occurred in approximately 5% of patients and were generally self-limited. Given that resmetirom accumulates in hepatocytes via active transport, transient enzyme elevations may reflect direct pharmacological stimulation of mitochondrial metabolism rather than toxicity.

Gallstone formation was observed at a numerically higher rate in the resmetirom group (2.6%) vs. Placebo (1.3%). Thyroid hormone analogues accelerate cholesterol conversion to bile acids, and increased biliary cholesterol saturation leading to cholelithiasis is a known class effect of thyromimetics. Baseline hepatic ultrasound to assess for gallstones before initiation is a reasonable clinical precaution.

Practical Dosing Guidance Based on PK Principles

Resmetirom is initiated at 80 mg once daily with food. Dose escalation to 100 mg is based on fibrosis stage and tolerability rather than plasma drug level monitoring, because no validated therapeutic drug monitoring assay is commercially available for resmetirom. Clinicians should instead use SHBG as an indirect marker of hepatic THR-beta engagement.

Patients taking gemfibrozil should switch to an alternative lipid-lowering agent before starting resmetirom. Patients on rosuvastatin should be transitioned to the lowest effective dose and monitored for myalgia at initiation. Digoxin levels should be checked within 2 weeks of starting resmetirom if the combination is unavoidable.

Monitor ALT, AST, and total bilirubin at baseline, at 3 months, and every 6 months thereafter. Dose interruption is appropriate if ALT rises to more than 5 times the upper limit of normal on two consecutive measurements.